MedTrace Logo

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

NCT04183712 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2024-10-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.

Conditions

  • Gallbladder Carcinoma

Interventions

DRUG

gemcitabine and oxaliplatin.

GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.

DRUG

Afatinib

Target therapy Drug: afatinib

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • The First Affiliated Hospital of Anhui Medical University

    collaborator OTHER

  • Shanghai East Hospital of Tongji University

    collaborator OTHER

  • Changshu Affiliated Hospital of Soochow University

    collaborator OTHER

  • Qinghai People's Hospital

    collaborator OTHER

  • The Second People's Hospital of Baoshan, Yunnan Province

    collaborator UNKNOWN

  • Lanzhou University Second Hospital

    collaborator OTHER

  • The Affiliated Hospital of Inner Mongolia Medical University

    collaborator OTHER

  • The First People's Hospital of Nantong

    collaborator UNKNOWN

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Yingbin Liu, PHD · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2025-06-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04183712 on ClinicalTrials.gov